Is An End To The Combination Therapy Pricing Problem In Sight In The UK?
Executive Summary
Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.
You may also be interested in...
UK’s Competition Body Says Pharma Firms Can Work Together On Access To Combination Therapies
The UK’s Competition and Markets Authority will not prioritize the investigation of pharmaceutical companies that enter commercial negotiations with the aim of making combination therapies cost effective, a move that the ABPI says is an “international first”.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.